Literature DB >> 27472306

Neoadjuvant chemoradiation treatment followed by surgery for esophageal cancer: there is much more than the mandard tumor regression score.

L Depypere1, J Moons1, T Lerut1, G De Hertogh2, X Sagaert2, W Coosemans1, H Van Veer1, A Renders1, P Nafteux1.   

Abstract

OBJECTIVE: Tumor regression grading (TRG) systems categorize residual tumor volume on the primary tumor after neoadjuvant treatment. Aim was to evaluate the impact of Mandard TRG, residual tumor depth (ypT) and residual lymph node status (ypN) and extent (ELNI) i.e. intracapsular versus extracapsular involvement on overall (OS) and disease-free survival (DFS) in esophageal carcinoma.
METHODS: Between 2005 and 2014, 344 patients receiving R0-esophagectomy after neoadjuvant chemoradiation therapy (nCRT) were selected. Mandard TRG, ypTN and ELNI were prospectively recorded.
RESULTS: Mandard TRG1 was found in 110 (32%); TRG2 in 120 (35%); TRG3 in 53 (15%); TRG4 in 54 (16%) and TRG5 in 7 (2%) patients. Both OS and DFS showed no significant difference between TRG1 and 2 (p = 0.059 and 0.105, respectively). Therefore, TRG1/2 was classified together as 'major response', TRG3/4 as 'minor response' and TRG5 as 'no response'. Multivariate analysis showed two independent prognosticators for OS (tumor regression response (TRR) and number of positive lymph nodes) and three independent prognosticators for DFS (TRR, ypT and ELNI).
CONCLUSION: After nCRT followed by surgery for esophageal carcinoma, number of residual positive lymph nodes as well as TRR are prognosticators for OS. Minor TRR, ypT and extracapsular lymph node invasion are prognosticators for recurrence.

Entities:  

Keywords:  Chemoradiotherapy; esophageal neoplasm; neoadjuvant therapy; surgical pathology

Year:  2016        PMID: 27472306     DOI: 10.1080/00015458.2016.1212500

Source DB:  PubMed          Journal:  Acta Chir Belg        ISSN: 0001-5458            Impact factor:   1.090


  3 in total

1.  The Impact of Tumor Regression on Prognosis After Neoadjuvant Chemoradiotherapy in Surgically Treated Esophageal Adenocarcinoma.

Authors:  D J Crull; M C H Hogenes; R Hoekstra; E M Hendriksen; M J van Det; E A Kouwenhoven
Journal:  Ann Surg Oncol       Date:  2022-01-29       Impact factor: 5.344

2.  Prognostic factors for survival in esophageal squamous cell carcinoma (ESCC) patients with a complete regression of the primary tumor (ypT0) after neoadjuvant chemoradiotherapy (NCRT) followed by surgery.

Authors:  Min Kong; Jianfei Shen; Chao Zhou; Haihua Yang; Baofu Chen; Chengchu Zhu; Gongchao Wang
Journal:  Ann Transl Med       Date:  2020-09

3.  ypT0N+: the unusual patient with pathological complete tumor response but with residual lymph node disease after neoadjuvant chemoradiation for esophageal cancer, what's up?

Authors:  Lieven Peter Depypere; Gil Vervloet; Toni Lerut; Johnny Moons; Gert De Hertogh; Xavier Sagaert; Willy Coosemans; Hans Van Veer; Philippe Robert Nafteux
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.